MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Auris Medical Holding AG Company Profile (NASDAQ:EARS)

Consensus Ratings for Auris Medical Holding AG (NASDAQ:EARS) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.33 (139.20% upside)

Analysts' Ratings History for Auris Medical Holding AG (NASDAQ:EARS)
Show:
DateFirmActionRatingPrice TargetActions
6/15/2016Leerink SwannReiterated RatingBuy$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/10/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/1/2015Needham & Company LLCReiterated RatingBuy$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/2/2014JMP SecuritiesInitiated CoverageOutperform$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Auris Medical Holding AG (NASDAQ:EARS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/17/2016        
5/11/2016Q116($0.23)($0.27)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2016Q415($0.28)($0.16)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.28)($0.15)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/19/2015Q215($0.23)($0.35)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/28/2015Q115($0.22)($0.29)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/19/2015Q4($0.23)($0.17)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
12/3/2014Q3($0.24)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/15/2014($0.34)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Auris Medical Holding AG (NASDAQ:EARS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.29)($0.22)($0.25)
Q2 20163($0.33)($0.25)($0.28)
Q3 20163($0.38)($0.26)($0.31)
Q4 20163($0.44)($0.22)($0.32)
(Data provided by Zacks Investment Research)
Dividend History for Auris Medical Holding AG (NASDAQ:EARS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Auris Medical Holding AG (NASDAQ:EARS)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Auris Medical Holding AG (NASDAQ:EARS)
DateHeadline
06/28/16 08:48 PMCould Auris Medical Holding AG Change Direction After Today's Huge Increase? - Engelwood Daily
06/28/16 03:42 PMAuris Medical Holding (EARS) Announces Completion of Keyzilen Phase 3 TACTT3 Enrollment - StreetInsider.com
06/28/16 07:31 AMAuris Medical Completes Enrollment of Phase 3 TACTT3 Trial with Keyzilen in Acute and Post-Acute Inner Ear Tinnitus - [at noodls] - Top-line results from TACTT3 trial expected in the fourth quarter Data to complement results from TACTT2 trial that are expected in August ZUG, Switzerland, June 28, 2016 (GLOBE NEWSWIRE) -- Auris Medical ...
06/27/16 03:43 PMAuris Medical Holding AG (EARS) Updated Price Targets - FTSE News
06/22/16 08:27 AMBiotech Losers: Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), Auris Medical Holding AG (NASDAQ:EARS), Infinity ... - KC Register
06/20/16 09:31 AMAuris (EARS) Begins Phase III Study for Sudden Deafness -
06/18/16 08:17 AMAuris Medical Holding (EARS) Begins AM-111 Phase 3 as Sudden Deafness Treatment - StreetInsider.com
06/17/16 08:10 AMAuris Medical Holding (EARS) Begins AM-111 Phase 3 as Sudden Deafness Treatment
06/17/16 07:08 AMAuris Medical Initiates ASSENT Phase 3 Trial of AM-111 for Treatment of Sudden Deafness - [GlobeNewswire] - ZUG, Switzerland -- Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced it ...
06/16/16 08:05 AMBiggest Moving Stocks Today – BCOM, PULM, AXDX, HMNY, EARS, CLRB, AKAO
06/16/16 07:39 AMAuris Medical to Present at the JMP Securities Life Sciences Conference on Wednesday, June 22 - [at noodls] - ZUG, Switzerland, June 16, 2016 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, ...
06/16/16 07:25 AMAuris Medical (EARS) Jumps: Stock Adds 15.2% in Session -
06/14/16 06:49 AMAuris Medical Hosts Key Opinion Leader Event Focused on Phase 3 Program for Acute Inner Ear Tinnitus - [at noodls] - Company introduces Keyzilen as brand name for AM-101 Keyzilen has potential to be first-ever approved therapy for tinnitus Live webcast of event begins today at 8 am EDT ZUG, Switzerland, June 14, 2016 ...
06/10/16 03:50 PMTrend Of Rating Given To Auris Medical Holding AG (NASDAQ:EARS) - Investor Newswire
06/07/16 09:24 PMAuris Medical to Host Key Opinion Leader Event Focused on Acute Inner Ear Tinnitus and AM-101's Phase 3 Program ... - Nasdaq
06/07/16 03:51 PMAuris Medical to Host Key Opinion Leader Event Focused on Acute Inner Ear Tinnitus and AM-101's Phase 3 Program ... - GlobeNewswire (press release)
06/07/16 09:40 AMAuris Medical to Host Key Opinion Leader Event Focused on Acute Inner Ear Tinnitus and AM-101s Phase 3 Program ... - EconoTimes
06/07/16 07:28 AMAuris Medical to Host Key Opinion Leader Event Focused on Acute Inner Ear Tinnitus and AM-101's Phase 3 Program on June 14 in New York City - [at noodls] - AM-101 has potential to be first-ever approved therapy for tinnitus Top-line results from first of two Phase 3 trials expected in August ZUG, Switzerland, June 7, 2016 (GLOBE NEWSWIRE) -- Auris Medical ...
06/06/16 01:33 PMAuris Medical Holding AG :EARS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 -
06/05/16 03:41 PMAfter Last Week What Do Analysts Think Of Auris Medical Holding AG (EARS) - Share Trading News
06/02/16 08:22 AMAuris Medical to Present at the Jefferies 2016 Healthcare Conference on Thursday, June 9 - PharmiWeb.com (press release) - Auris Medical to Present at the Jefferies 2016 Healthcare Conference on Thursday, June 9PharmiWeb.com (press release)ZUG, Switzerland, June 2, 2016 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that ...and more »
06/02/16 07:15 AMAuris Medical to Present at the Jefferies 2016 Healthcare Conference on Thursday, June 9 - [at noodls] - ZUG, Switzerland, June 2, 2016 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, ...
06/01/16 03:56 PMBuy, Sell Or Hold Rating For Auris Medical Holding AG (EARS)? - Share Trading News - Buy, Sell Or Hold Rating For Auris Medical Holding AG (EARS)?Share Trading NewsAuris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute ...
05/11/16 07:00 AMAuris Medical Holding AG Earnings Call scheduled for 8:00 am ET today -
05/11/16 06:07 AMQ1 2016 Auris Medical Holding AG Earnings Release - Before Market Open -
05/11/16 05:51 AMAuris reports 1Q loss -
05/04/16 07:40 AMAuris Medical to Announce First Quarter 2016 Financial Results and Host Conference Call on Wednesday, May 11, 2016 - [at noodls] - ZUG, Switzerland, May 4, 2016 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, ...
04/05/16 01:37 PMEdited Transcript of EARS earnings conference call or presentation 14-Mar-16 12:00pm GMT -
04/05/16 06:17 AMAuris Medical to Present at the 15th Annual Needham Healthcare Conference on Tuesday, April 12 - [at noodls] - ZUG, Switzerland, April 05, 2016 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in ...
03/30/16 05:49 AMAuris Medical Completes Enrollment of TACTT2 Phase 3 Trial of AM-101 in Acute Inner Ear Tinnitus - [at noodls] - Basel, Switzerland, March 30, 2016 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in ...
03/28/16 07:33 AMWhy You Shouldn't Bet Against Auris Medical (EARS) Stock -
03/14/16 11:43 AMAuris Medical Holding (EARS) Reports Q4 Loss of CHF0.16/Share - Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. Auris Medical Holding (NASDAQ: EARS) reported Q4 EPS of (CHF0.16), versus (CHF0.17) reported last year. "We achieved significant progress with our development programs in ...
03/14/16 07:22 AMAuris reports 4Q loss -
03/14/16 06:07 AMQ4 2015 Auris Medical Holding AG Earnings Release - Before Market Open -
03/14/16 05:37 AM6:37 am Auris Medical beats by CHF 0.12, provides corporate update -
03/11/16 07:55 AMWhy Auris Medical Holding (EARS) Might Surprise This Earnings Season -
03/02/16 05:03 AMAuris Medical to Announce Fourth Quarter and Full Year 2015 Financial Results and Host Conference Call on Monday, March 14, 2016 - [GlobeNewswire] - ZUG, Switzerland -- Auris Medical Holding AG (Nasdaq: EARS) today announced that it will release its financial results for the fourth quarter and full year 2015, on Monday, March 14, 2016. Following the ...
02/26/16 09:54 AMAuris Medical Holding AG's Trend Up, Especially After Today's Strong Session - Business Standard Tribune - Auris Medical Holding AG's Trend Up, Especially After Today's Strong SessionBusiness Standard TribuneThe stock of Auris Medical Holding AG (NASDAQ:EARS) is a huge mover today! The stock increased 5.64% or $0.25 on February 25, hitting $4.68. About 300,774 shares traded hands or 15.83% up from the average. Auris Medical Holding AG ...
02/18/16 08:05 AMAuris Medical to Host Key Opinion Leader Meeting and Webcast Focused on Acute Sensorineural Hearing Loss on February 26 in New York City - [GlobeNewswire] - ZUG, Switzerland -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced ...
02/14/16 12:20 PMAuris Medical Up More Than 18% As Swiss Bank Zurcher Kantonalbank Acquires 2.2 Million Shares (NASDAQ:EARS) - WallStreet.org - Auris Medical Up More Than 18% As Swiss Bank Zurcher Kantonalbank Acquires 2.2 Million Shares (NASDAQ:EARS)WallStreet.orgAuris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its lead product candidate includes AM-101, which is in Phase III clinical development for ...
02/14/16 12:20 PMAuris Medical Holding AG (NASDAQ:EARS) Shorted Shares Increased 11.01% After Market Selling - fdanewsalert.com - Auris Medical Holding AG (NASDAQ:EARS) Shorted Shares Increased 11.01% After Market Sellingfdanewsalert.comThe stock of Auris Medical Holding AG (NASDAQ:EARS) registered an increase of 11.01% in short interest. EARS's total short interest was 374,200 shares in February as published by FINRA. Its up 11.01% from 337,100 shares, reported previously.
02/12/16 07:15 AMFibroGen (FGEN) Shows Strength: Stock Moves Up 14% -
02/11/16 01:24 PMAuris Medical Holding AG (NASDAQ:EARS): Favorite Pick - Stocks Daily - Auris Medical Holding AG (NASDAQ:EARS): Favorite PickStocks DailyZacks Research, a reputed firm in the market, planned a poll of sell-side analysts. Going by this poll, Auris Medical Holding AG (NASDAQ:EARS) was given rating of 1. Zacks uses a scale on which the companies are given ratings on a scale of 1 to 5.and more »
02/09/16 12:49 PMAuris Medical Holding AG (NASDAQ:EARS) Sellers Increased By 543.32% Their Shorts - fdanewsalert.com - Auris Medical Holding AG (NASDAQ:EARS) Sellers Increased By 543.32% Their Shortsfdanewsalert.comThe stock of Auris Medical Holding AG (NASDAQ:EARS) registered an increase of 543.32% in short interest. EARS's total short interest was 337,100 shares in February as published by FINRA. Its up 543.32% from 52,400 shares, reported previously.Analysts Set $12.00 Target Price for Auris Medical Holding AG (NASDAQ:EARS)Daily Politicalall 2 news articles »
02/06/16 01:34 PMAuris Medical to Present at the 2016 Leerink Global Healthcare Conference on Thursday, February 11 - Stockhouse - Auris Medical to Present at the 2016 Leerink Global Healthcare Conference on Thursday, February 11StockhouseZUG, Switzerland, Feb. 5, 2016 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will ...and more »
02/05/16 12:31 PMAuris Medical to Present at the 2016 Leerink Global Healthcare Conference on Thursday, February 11 - GlobeNewswire (press release) - Auris Medical to Present at the 2016 Leerink Global Healthcare Conference on Thursday, February 11GlobeNewswire (press release)ZUG, Switzerland, Feb. 5, 2016 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will ...and more »
02/05/16 07:42 AMAuris Medical to Present at the 2016 Leerink Global Healthcare Conference on Thursday, February 11 - [GlobeNewswire] - ZUG, Switzerland -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced ...
02/02/16 12:04 PMAuris Medical Holding AG (EARS) Recent Analyst Updates - Risers & Fallers - Auris Medical Holding AG (EARS) Recent Analyst UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of Auris Medical Holding AG (EARS). According to the latest broker reports outstanding on Tuesday 2nd February, 2 analysts have a rating of “strong buy”, 2 analysts “buy ...
02/01/16 11:50 AMCompany Shares of Auris Medical Holding AG (NASDAQ:EARS) Rally 6.92% - Bull Report - Company Shares of Auris Medical Holding AG (NASDAQ:EARS) Rally 6.92%Bull ReportShares of Auris Medical Holding AG (NASDAQ:EARS) appreciated by 6.92% during the past week but lost 8.38% on a 4-week basis. The shares have outperformed the S&P 500 by 5.08% in the past week but underperformed the index by 3.49% in the last 4 ...
01/28/16 06:48 PMAuris Medical Holding AG - Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its lead product candidate includes AM-101, which is in Phase III clinical development for treating ...
About Auris Medical Holding AG

Auris Medical Holding AG logoAuris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration. Its second product candidate, AM-111, is being developed for the treatment of acute sensorineural hearing loss (ASNHL). It intends to conduct over two pivotal Phase III trials in the treatment of idiopathic sudden SNHL (ISSNHL), titled Acute Inner Ear Hearing Loss (HEALOS) and Acute Sudden Sensorineural Hearing Loss Treatment (ASSENT). AM-111 received orphan drug designation for the treatment of ASNHL from the United States Food and Drug Administration, and the European Union agency. It intends to conduct a Phase II trial in the treatment of surgery-induced hearing loss (REACH).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EARS
  • CUSIP:
Key Metrics:
  • Previous Close: $4.32
  • 50 Day Moving Average: $3.59
  • 200 Day Moving Average: $4.06
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $148.30M
  • Current Quarter EPS Consensus Estimate: $-1.01 EPS
Additional Links:
Auris Medical Holding AG (NASDAQ:EARS) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha